Long-Term Clinical Consequences of Patients Hospitalized for COVID-19 Infection

Özcan, Sevgi; İnce, Orhan; Güner, Ahmet; Katkat, Fahrettin; Dönmez, Esra; Tuğrul, Sevil; Şahin, İrfan; Okuyan, Ertuğrul; Kayıkçıoğlu, Meral

doi:10.5152/anatoljcardiol.2022.924

Cited by 4 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of twelve studies offering insights into the development of arterial hypertension following a COVID-19 infection were identified [38][39][40][41][42][43][44][45][46][47][48][49].…”

Section: New Arterial Hypertension Developmentmentioning

confidence: 99%

“…In Özcan's [42] study, HTN was defined as a value of systolic blood pressure ≥ 140 mm Hg and diastolic blood pressure ≥ 90 mm Hg measured with the patient supine or a history of antihypertensive medication use. Akpek et al [43] defined new onset hypertension as presenting values of ≥140 mmHg systolic BP and/or ≥90 mmHg diastolic BP in office measurements and ≥135 mmHg systolic BP and/or ≥85 mmHg diastolic BP in home BP monitoring according to the European Society of Cardiology guidelines.…”

Section: New Arterial Hypertension Developmentmentioning

confidence: 99%

“…Data collection in the majority of the studies was accomplished through telephone surveys [38,40,42,45,46,49] or by examining medical records [39,48]. Mei et al [39] diagnosed hypertension in 6 individuals (0.16%), although the specific diagnostic verification method was not specified.…”

Section: New Arterial Hypertension Developmentmentioning

confidence: 99%

“…Mei et al [39] diagnosed hypertension in 6 individuals (0.16%), although the specific diagnostic verification method was not specified. In contrast, Sergi Ozcan [42] employed ambulatory blood pressure monitoring (ABPM) to detect four new cases of high blood pressure. Vyas et al [47] not only assessed blood pressure but also examined laboratory parameters and chest computed tomography (CT) scans.…”

Section: New Arterial Hypertension Developmentmentioning

confidence: 99%

See 3 more Smart Citations

Elevated Arterial Blood Pressure as a Delayed Complication Following COVID-19—A Narrative Review

Bielecka,

Sielatycki,

Pietraszko

et al. 2024

IJMS

View full text Add to dashboard Cite

Arterial hypertension is one of the most common and significant cardiovascular risk factors. There are many well-known and identified risk factors for its development. In recent times, there has been growing concern about the potential impact of COVID-19 on the cardiovascular system and its relation to arterial hypertension. Various theories have been developed that suggest a connection between COVID-19 and elevated blood pressure. However, the precise link between SARS-CoV-2 infection and the long-term risk of developing hypertension remains insufficiently explored. Therefore, the primary objective of our study was to investigate the influence of COVID-19 infection on blood pressure elevation and the subsequent risk of developing arterial hypertension over an extended period. To accomplish this, we conducted a thorough search review of relevant papers in the PubMed and SCOPUS databases up to 3 September 2023. Our analysis encompassed a total of 30 eligible articles. Out of the 30 papers we reviewed, 19 of them provided substantial evidence showing a heightened risk of developing arterial hypertension following COVID-19 infection. Eight of the studies showed that blood pressure values increased after the infection, while three of the qualified studies did not report any notable impact of COVID-19 on blood pressure levels. The precise mechanism behind the development of hypertension after COVID-19 remains unclear, but it is suggested that endothelial injury and dysfunction of the renin–angiotensin–aldosterone system may be contributory. Additionally, changes in blood pressure following COVID-19 infection could be linked to lifestyle alterations that often occur alongside the illness. Our findings emphasize the pressing requirement for thorough research into the relationship between COVID-19 and hypertension. These insights are essential for the development of effective prevention and management approaches for individuals who have experienced COVID-19 infection.

show abstract

“…A total of twelve studies offering insights into the development of arterial hypertension following a COVID-19 infection were identified [38][39][40][41][42][43][44][45][46][47][48][49].…”

Section: New Arterial Hypertension Developmentmentioning

confidence: 99%

Section: New Arterial Hypertension Developmentmentioning

confidence: 99%

Section: New Arterial Hypertension Developmentmentioning

confidence: 99%

Section: New Arterial Hypertension Developmentmentioning

confidence: 99%

See 2 more Smart Citations

Elevated Arterial Blood Pressure as a Delayed Complication Following COVID-19—A Narrative Review

Bielecka,

Sielatycki,

Pietraszko

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Echocardiography was performed on patients 3-6 months after PCR positivity. In this time period selection, we chose previously published literature data as referances [12][13][14]. Two-dimensional transthoracic doppler echocardiography (Vivid 7, GE Vingmed, 2.5 MHz, USA) was used for measurements.…”

Section: Doppler Echocardiographymentioning

confidence: 99%

Hidden enemy of pulmonary arteries: COVID-19

Duygu,

Kucuk

2024

Med-Science

View full text Add to dashboard Cite

It has been reported that COVID-19 may cause severe endothelial damage. Pulmonary Artery Stiffness (PAS) is a strong predictor of right ventricular function. PAS can reveal important information about the endothelial functions of the pulmonary bed. In this study, we aimed to elucidate the possible effect of COVID-19 on PAS. The study was performed by measuring PAS values with transthoracic echocardiography in 130 patients, 60 of whom had COVID-19 and 70 were controls. COVID-19 patients with positive polymerase chain reaction (PCR) test results were included in the study 3-6 months after their positivity. When the Maximal frequency shift (MFS) (Hz) results were examined, no significant difference was observed between the patient and control groups (2764±279.24 and 2664.8±673.91 p=0.340, respectively). There was a significant difference between the patient and control groups in favor of the patient group in pulmonary acceleration time (PAT) (msec) results (93.18±14.99 and 126.1±17.58, respectively, p<0.001). There was a significant difference between the patient and control groups in favor of the patient group in PAS (Hz/msec) results (30.28±5.07 and 21.57±7.04, respectively, p<0.001). It is possible that COVID-19 may have adverse effects on the pulmonary artery wall and bed. As a result of endothelial damage due to COVID-19, an increase in PAS values can be observed.

show abstract

Persistent chest pain following COVID‐19 infection – A scoping review

Kubrova,

Hallo‐Carrasco,

Klasova

et al. 2024

PM&R

View full text Add to dashboard Cite

IntroductionPersistent chest pain (PCP) following acute COVID‐19 infection is a commonly reported symptom with an unclear etiology, making its management challenging. This scoping review aims to address the knowledge gap surrounding the characteristics of PCP following COVID‐19, its causes, and potential treatments.ObjectiveTo assess the prevalence, causes, and potential treatments of PCP following COVID‐19 infection.DesignA scoping review of 64 studies, including observational (prospective, retrospective, cross‐sectional, case series, and case‐control) and one quasi‐experimental study, from databases including Embase, PubMed/MEDLINE, Cochrane CENTRAL, Google Scholar, Cochrane Database of Systematic Reviews, and Scopus.SettingStudies on patients with PCP following mild, moderate, and severe COVID‐19 infection.PatientsStudies that included patients of any age, with chest pain that persisted following acute COVID‐19 disease, irrespective of etiology or duration.InterventionsNot applicable.Main Outcome Measure(s)Prevalence, causes, and potential treatments of PCP following COVID‐19 infection.ResultsA total of 35 studies reported PCP symptoms following COVID‐19 (0.24‐76.6%) at an average follow‐up of three months or longer, 12 studies at 1‐3 months and 17 studies at less than one month follow‐up or not specified. PCP was common following mild ‐ severe COVID‐19 infection, and etiology was mostly not reported. Fourteen studies proposed potential etiologies including endothelial dysfunction, cardiac ischemia, vasospasm, myocarditis, cardiac arrhythmia, pneumonia, pulmonary embolism, postural tachycardia syndrome (POTS), or noted cardiac MRI (cMRI) changes. Evaluation methods included common cardiopulmonary tests, as well as less common tests such as flow‐mediated dilatation (FMD), cMRI, single‐photon emission computed tomography myocardial perfusion imaging (SPECT‐MPI), and cardiopulmonary exercise testing (CPET). Only one study reported a specific treatment (sulodexide).ConclusionsPCP is a prevalent symptom following COVID‐19 infection, with various proposed etiologies. Further research is needed to establish a better understanding of the causes and to develop targeted treatments for PCP following COVID‐19.This article is protected by copyright. All rights reserved.

show abstract

Long-Term Clinical Consequences of Patients Hospitalized for COVID-19 Infection

Cited by 4 publications

References 32 publications

Elevated Arterial Blood Pressure as a Delayed Complication Following COVID-19—A Narrative Review

Elevated Arterial Blood Pressure as a Delayed Complication Following COVID-19—A Narrative Review

Hidden enemy of pulmonary arteries: COVID-19

Persistent chest pain following COVID‐19 infection – A scoping review

Contact Info

Product

Resources

About